Physician profile
Benjamin Michael Werling
NPI 1578057485
$2,531.79
in general payments reported to CMS, 2019-2025
24 companies · $525 in 2025
The $525 reported for 2025 was more than what 75% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $522 · 2022: $583 · 2023: $529 · 2024: $373 · 2025: $525.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,427.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,426.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $793.33 | 2021-2025 | Farxiga, Airsupra, Breztri |
| Abbvie INC. | $435.76 | 2021-2023 | |
| Novo Nordisk INC | $367.81 | 2021-2025 | Wegovy, Ozempic, Rybelsus |
| Abbott Laboratories | $165.52 | 2022-2025 | Freestyle Libre 3 |
| Idorsia Pharmaceuticals US INC | $89.04 | 2022-2024 | Quviviq |
| Exact Sciences Corporation | $85.45 | 2023-2025 | Cologuard Collection Kit, The Cologuard Plus Collection Kit |
| Amgen INC. | $74.78 | 2021-2024 | Repatha, Otezla, Prolia |
| Lilly USA, LLC | $66.23 | 2021-2022 | |
| Boston Scientific Corporation | $56.66 | 2021 | |
| Sanofi-Aventis U.S. LLC | $52.51 | 2021-2023 | |
| Pfizer INC. | $44.51 | 2022-2024 | |
| Aimmune Therapeutics, INC. | $33.93 | 2024-2025 | Zenpep |
| Boehringer Ingelheim Pharmaceuticals, INC. | $33.54 | 2023 | Tradjenta, Jardiance |
| Glaxosmithkline, LLC. | $32.60 | 2021-2023 | Trelegy Ellipta |
| E.R. Squibb & Sons, L.L.C. | $31.18 | 2022 |
Show all 24 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Pharmaceuticals, INC | $29.87 | 2022-2025 | Spravato |
| Currax Pharmaceuticals LLC | $29.34 | 2021-2025 | Contrave |
| Ascensia Diabetes Care US INC. | $23.35 | 2025 | |
| Novartis Pharmaceuticals Corporation | $22.38 | 2023 | |
| Medtronic, INC. | $15.52 | 2025 | Kyphon Express II Kyphopak Tray |
| Biohaven Pharmaceutical Holding Company LTD. | $14.63 | 2022 | |
| Otsuka America Pharmaceutical, INC. | $13.64 | 2023 | Rexulti |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $11.04 | 2021 | |
| Genentech USA, INC. | $9.17 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Benjamin Werling listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.